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journa l homepage : www.e lsev ie r . com/ loca te / rmedLETTER TO THE EDITORCOPD patients with higher education are much less
likely to adhere to prescribed daily inhaler useThis was one of the results from a survey of 265 patients
with COPD in Colorado.1 I agree with the 40% of patients
who ‘‘vary their inhaler use from what is prescribed’’. The
only proven value of any of these medications is either to
relieve dyspnea (for the duration of the bronchodilation)2
or slightly lower the risk of an exacerbation, but not to
suppress the rapid loss of lung function.3e7 (Post hoc and
subgroup analyses don’t count.) Only smoking cessation
halts progression of COPD,8 but it is much easier to write
a prescription for an inhaler than to help a patient through
the process of smoking cessation.
Bronchodilators bronchodilate almost everyone to some
degree: those with asthma, COPD, and people with healthy
airways.9 However, that is not a valid rationale for urging
everyone to take long-acting bronchodilators every day. If
the patient does not feel any relief from dyspnea within an
hour after taking a bronchodilator inhaler, then they are not
a responder to that beta-agonist or anticholinergic medica-
tion and are correct in assuming that they don’t need it,
despite the optimism of the physician who prescribed it.
Patients with an FEV1 >50% of predicted (which included
more than half of those who responded to the Colorado
survey) are highly unlikely to have either dyspnea due to
their lung disease10 nor a COPD exacerbation requiring
hospitalization.11 The source of dyspnea on exertion in
patients with such mild physiologic impairment is probably
obesity or poor cardiovascular conditioning.
For the minority whose dyspnea does noticeably improve
after inhaling a bronchodilator, ‘‘as needed’’ dosing with an
inexpensive, generic, short-acting salbutamol or ipra-
tropium solution ($4 per month in the United States) by
nebulizer or inhaler (inexpensive outside of the United
States) is probably the optimal treatment. For patients with
an FEV1 above 50% predicted, and whose dyspnea occurs
only once or twice during daytime exertion, taking a long-
acting bronchodilator in the morning may only be a more
attractive option for a minority of patients when compared
to taking a short-acting bronchodilator as needed for
dyspnea. Perhaps that’s why the patients in Colorado with
an education beyond high school were twice as likely to
self-manage their COPD based on their symptoms and
response to the prescribed therapy.10954-6111/$ - see front matter ª 2010 Elsevier Ltd. All rights reserved
doi:10.1016/j.rmed.2009.10.031Tiotropium inhalers are indeed convenient, but expen-
sive, and risk cardiovascular side-effects12,13 (despite the
claims of industry-sponsored investigators). Combination
inhalers approved for COPD are also very expensive and
have high doses of corticosteroids, which have been proven
to substantially increase the risk of pneumonia.4,14,15 For
those with more severe COPD, the cost of two weeks of
treatment of a mild COPD exacerbation with an antibiotic
and prednisone once per year (the usual care and mean
exacerbation rate) is much less than the cost of daily
compliance with tiotropium or a combination inhaler. Given
the facts, an educated patient with severe COPD might
reasonably decide that taking a prophylactic inhaler every
day for several years just to prevent a single hospitalization
may not be worth their time and expense.
More broad surveys of patients with COPD are needed to
illuminate the true spectrum of response to available
therapies e not just mean responses from groups of
patients carefully selected by drug company investiga-
tors.16,17 Much more research is necessary to help guide
clinicians to customize COPD therapy for each patient, for
example, based on their responses to individual interven-
tions, instead of using cookbook or shotgun medicine.
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